A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer
Upon determination of eligibility, patients will be randomly assigned to one of two
treatment arms:
Docetaxel Docetaxel + Gemcitabine
For ever 2 patients treated, 1 will receive treatment A (docetaxel) and 1 will receive
treatment B (Docetaxel + Gemcitabine). The study is not blinded so both the patient and the
doctor will know which treatment has been assigned.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
median survival
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 52
NCT00193323
August 2001
January 2009
Name | Location |
---|---|
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |